Heart failure, platelet activation and inhibition of the renin-angiotensin-aldosterone system

Archives des Maladies du Coeur et des Vaisseaux

Volumn 97, Issue 9, 2004, Pages 889-893

  Bauersachs, J ^a   Schafer A ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Aldosterone; Angiotensin; Endothelial function; Heart failure; Nitric oxide; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; NITRIC OXIDE; SPIRONOLACTONE; TRANDOLAPRIL; WARFARIN;

BLOOD VESSEL TONE; CLINICAL TRIAL; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART VENTRICLE REMODELING; HUMAN; HYPERCOAGULABILITY; LUNG CONGESTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SINUS RHYTHM; STROKE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOSIS;

EID: 4644320154     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-52.
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-02.
3. Dunkman WB, Johnson GR, Carson PE et al. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: VI94-101.
4. Loh I, St John Sutton M, Wun CC. Ventricular dysfunction and the risk of stroke offer myocardial infarction. N Engl J Med 1997; 336: 251-7.
5. Gibbs CR. Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic neart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103: 1746-51.
6. Lip GY, Gibbs CR. Does heart failure confer a hypercoaguloble state? Virchow's triad revisited. J Am Coll Cardiol 1999; 33: 1424-6.
7. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JS, Konstan MA. Warfarin anticoagulation and survival: A cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol 1998; 31: 749-53.
8. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalopril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
9. Falk RH, Pollak A, Tandon PK, Packer M. The effect of warfarin on prevalence of stroke in patients with severe heart failure. J Am Coll Cardiol 1993; 21: 218A. Abstract.
10. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38: 2101-13.
11. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101: 2981-8.
12. Teerlink JR, Loffler BM, Hess P et al. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994; 90: 2510-8.
13. Fraccarollo D, Galuppo P, Hildemann S et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003; 42: 1666-73.
14. Ertl G. Angiotensin converting enzyme inhibitors in angino and myocardial infarction. What role will they play in the 1990s? Drugs 1993; 46: 209-18.
15. Ertl G, Goudron P, Neubauer S et al. Cardiac dysfunction and development of heart failure. Eur Heart J 1993; 14 (Suppl. A): 33-7.
16. Bauersachs J, Schäfer A. Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches. Curr Vase Pharmacol 2004; 2: 115-24.
17. Drexler H. Endothelium as a therapeutic target in heart failure. Circulation 1998; 98: 2652-5.
18. Ontkean M, Gray R, Greenberg, B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 1991; 69: 1088-96.
19. Schäfer A, Fraccarollo D, Hildemann S et al. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 2003; 58: 655-62.
20. Bauersachs J, Bauloumié A, Fraccarollo D et al. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guonylyl cyclase expression: role of enhanced vascular superoxide production. Circulation 1999; 100: 292-8.
21. Keith M, Geranmayegan A, Sole MJ et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 1352-6.
22. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
23. Virdis A, Neves MF, Amiri F et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40: 504-10.
24. Lombes M, Alfaidy N, Eugene E et al. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175-82.
25. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-8.
26. Lamontagne D, Pohl U, Busse R. Mechanical deformation of vessel wall and shear stress determine the basal release of endothelium-derived relaxing factor in the intact rabbit coronary vascular bed. Circ Res 1992; 70: 123-30.
27. Pohl U, Nolte C, Bunse A, Eigenthaler M, Walter U. Endothelium-dependent phosphorylation of vasodilator-stimulated protein in platelets during coronary passage. Am J Physiol 1994; 266: H606-H612.
28. Andrews NP, Husain M, Dakak N, Quyyumi AA. Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction. J Am Coll Cardiol 2001; 37: 510-6.
29. Schäfer A, Wiesmann F, Neubauer S et al. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004; 109: 1819-22.
30. Corseaux D, Ollivier V, Fontaine V et al. Memostasis imbalance in experimental hypertension. Mol Med 2002; 8: 169-78.
31. Anderson RA, Ellis GR, Chirkov YY et al. Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure. Eur J Heart Fail 2004; 6: 47-54.
32. Chirkov YY, Holmes AS, Martelli JD, Horowitz JD. Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction. Am J Cardiol 2004; 93: 1438-40.
33. O'Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999; 83: 1345-9.
34. Stumpf C, Lehner C, Eskafi S et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003; 5: 629-37.
35. Mehta J, Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation 1979; 60: 497-503.
36. Schäfer A, Fraccarollo D, Hildemann S et al. Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and ACE inhibition: Role of endothelial function and platelet VASP phosphorylation. Thromb Haemost 2003; 89: 1024-30.
37. Lopez-Farre A, Sanchez de Miguel L, Monton M et al. Angiotensin II AT1 receptor antagonists and platelet activation. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 45-9.
38. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 2000; 11: 61-9.
39. Schwemmer M, Sommer O, Bassenge E. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc Drugs Ther 2001; 15: 301-7.
40. Nunez A, Gomez J, Zalba LR et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsarton. J Renin Angiotensin Aldosterone Syst 2000; 1: 175-9.
41. Bauersachs J, Fraccarollo D. Aldosterone antagonism in addition to ongiotensin-converting enzyme inhibitors in heart failure. Minerva Cardioangiol 2003; 51: 155-64.
42. Bauersachs J, Heck M, Froccarollo D et al. Addition of spironolactone to ACE inhibitor in heart failure improves endothelial vasomotor dysfunction: Role of vascular Superoxide anion formation and endothelial NO synthase expression. J Am Coll Cardiol 2002; 39: 351-8.
43. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6.
44. Pitt B, Zannand F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Enql J Med 1999; 341: 709-17.
45. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.